Adults with moderate-to-severe atopic dermatitis who were treated with Dupixent (dupilumab) from Sanofi and Regeneron along with topical corticosteroids experienced improvements in overall disease severity, according to results from phase 3 of the CAFÉ trial.
Adults with moderate-to-severe atopic dermatitis who were treated with Dupixent (dupilumab) from Sanofi and Regeneron along with topical corticosteroids experienced improvements in overall disease severity, according to results from phase 3 of the CAFÉ trial. The findings were presented at the 26th European Academy of Dermatology and Venereology Congress, which met September 13-17 in Geneva, Switzerland.
The study was assessing the proportion of patients who achieved a 75% or greater improvement in the Eczema Area and Severity Index (EASI-75) score, which is used to measure extent and severity of disease, at 16 weeks from baseline. The study included 325 patients in Europe with moderate-to-severe atopic dermatitis who were inadequately controlled with, or intolerant to, the broad immunosuppressant drug cyclosporine A or for whom the treatment was medically inadvisable.
Patients were randomized into 3 treatment groups and received topical corticosteroids with either a weekly or biweekly treatment with Dupixent or a placebo.
The researchers found that 59% of patients receiving Dupixent weekly with topical corticosteroids and 63% of patients receiving Dupixent every 2 weeks with topical corticosteroids achieved EASI-75. Only 30% of those receiving the placebo achieved EASI-75.
"In moderate-to-severe atopic dermatitis, some patients stop cyclosporine therapy due to intolerance or lack of efficacy, or are not candidates because of other medical conditions or contraindicated medications," Marjolein De Bruin-Weller, MD, PhD, dermatologist, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, said in a statement. "In the CAFÉ study, Dupixent with topical corticosteroids significantly improved overall measures of disease severity including lesions, itch, quality-of-life measures, and symptoms of anxiety and depression in these patients.”
From baseline to 16 weeks, the mean percent change improvement in EASI was 78% for weekly patients and 80% for patients receiving Dupixent every 2 weeks, respectively. Those receiving placebo had a mean percent change improvement of just 47%.
The 3 arms of the study had similar proportions of patients reporting adverse events. However, conjunctivitis was more frequently in patients receiving Dupixent—16% for weekly patients and 28% in patients receiving every 2 weeks—compared with 11% of patients on placebo. In addition, 11% of patients receiving Dupixent weekly and 4% receiving it every 2 weeks reported injection site reactions compared with 5% of patients receiving placebo. However, more patients receiving placebo reported skin infections (8%) compared with patients receiving Dupixent weekly (4%) or every 2 weeks (2%).
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More